Clinical trials: SARS-COV2 Virus
COVID-19
Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19
The primary objectives are: Pooled Phase 3 (Cohort 1) and Phase 2 (Cohort 1A) To evaluate the virologic efficacy of REGN10933+REGN10987 compared to placebo in reducing viral load of SARS-CoV-2 To evaluate the clinical efficacy of…
- Trial name
- NCT04426695
- Testing
- REGN10933+REGN10987 combination therapy
- Where
- 123 sites in United States, Brazil and 4 more
- Volunteers
- 2,252 people
- Sponsor
- Regeneron Pharmaceuticals
SARS-CoV-2
A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19
The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection.
- Trial name
- TeenCove (NCT04649151)
- Testing
- mRNA-1273, mRNA-1273.222
- Where
- 53 sites in United States, Dominican Republic
- Volunteers
- 4,328 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19
Safety and Immunogenicity Study of EgyVax Vaccine Candidate for Prophylaxis of COVID-19 Infection
This is a phase I, prospective, three-arm, open-label, randomized, first in human (FIH) clinical trial to assess the safety and immunogenicity of EgyVax vaccine candidate for prophylaxis of SARS-CoV-2 infection (COVID-19).
- Trial name
- Sphinx (NCT05218070)
- Testing
- EgyVax Vaccine Candidate
- Where
- Egypt
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Eva Pharma
Covid19
Study of Socio-demographic Factors, Behaviors and Practices Associated With Infection With SARS-CoV-2 Responsible for COVID-19
The objective of the study is to identify socio-demographic factors, behaviors and practices associated with infection with SARS-CoV-2 to help determine where and how patients mostly get infected with SARS-CoV-2.
- Trial name
- ComCor (NCT04607941)
- Testing
- Questionnaires, Phone interviews
- Where
- 2 sites in France
- Volunteers
- 766,818 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
COVID-19
Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years
This is a Phase 2/3 randomized, observer-blinded, placebo-controlled, age de-escalation trial to evaluate the safety and immunogenicity of 2 primary doses of SARS-CoV-2 rS with Matrix-M™ adjuvant (NVX-CoV2373) given 21 days apart…
- Trial name
- COVID-19 (NCT05468736)
- Testing
- SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)
- Where
- 94 sites in United States, Colombia and 8 more
- Volunteers
- 3,600 people, healthy volunteers welcome
- Sponsor
- Novavax
COVID-19, SARS-CoV-2
Control of COVID-19 Outbreaks in Long Term Care
To address the need to intervene to prevent the spread of COVID-19 in long-term care homes, we propose a randomized clinical trial of chemoprophylaxis in long-term care homes experiencing COVID-19 outbreaks.
- Trial name
- NCT04448119
- Testing
- Favipiravir
- Where
- Canada
- Volunteers
- 67 people
- Sponsor
- Appili Therapeutics Inc.
Respiratory Viral Infection
Clinical Evaluation of SARS-COV-2 (COVID-19), Influenza and RSV 8-Well MT-PCR Panel for In Vitro Diagnostics
This study is a prospective accuracy observational study to evaluate the performance of the Highplex System SARS-Cov-2, Influenza and RSV 8-well in vitro diagnostic medical device panel and generate performance data.
- Trial name
- NCT05946538
- Testing
- SARS-COV-2, Influenza and RSV 8-Well MT-PCR Panel, BioFire Respiratory Panel 2.1
- Volunteers
- 1,000 people
- Sponsor
- AusDiagnostics Pty Ltd.
Covid-19 Vaccine
A Phase II/III Study of PIKA Recombinant SARS-CoV-2 Vaccine as a Booster Dose.
This is a Phase II/III, randomized, double-blinded study in adults ≥ 18 years old who received 2 or more doses of inactivated COVID-19 vaccine to evaluate the efficacy, safety and immunogenicity of a booster dose of PIKA COVID-19…
- Trial name
- NCT05463419
- Testing
- PIKA COVID-19 vaccine, Inactivated Covid-19 vaccine
- Where
- 6 sites in Philippines, United Arab Emirates
- Volunteers
- 5,860 people, healthy volunteers welcome
- Sponsor
- Yisheng Biopharma (Singapore) Pte. Ltd.
Covid19
The Safety and Efficacy of Pyronaridine-artesunate (Pyramax® or Artecom®)in COVID-19 Patients
This is a multi-center, randomized, Phase 2/3 study to evaluate the safety and efficacy of pyronaridine-artesunate in participants with corona virus disease 2019 (COVID-19).
- Trial name
- PROVIDENCE (NCT04701606)
- Testing
- Artecom® (pyronaridine-artesunate)
- Where
- 4 sites in Philippines
- Volunteers
- 402 people
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
Covid19, SARS CoV-2
Capturing Infectious COVID-19 Asymptomatic Cases in Singapore
This study is being conducted to assess the performance of the BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2, used in serial testing, in identification of infectious, asymptomatic individuals.
- Trial name
- NCT04812327
- Testing
- BD Veritor Plus System for Rapid Detection of SARS CoV-2, rt-PCR, viral culture
- Where
- Singapore
- Sponsor
- Becton, Dickinson and Company
COVID-19
A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called Nirmatrelvir/Ritonavir) for the possible treatment of COVID-19.
- Trial name
- NCT05438602
- Testing
- Nirmatrelvir, Ritonavir
- Where
- 84 sites in United States, Australia and 7 more
- Volunteers
- 158 people
- Sponsor
- Pfizer
COVID-19, Viral Respiratory Illnesses
Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection
Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2…
- Trial name
- NCT04359680
- Testing
- Nitazoxanide, Vitamin Super B-Complex
- Where
- 26 sites in United States
- Volunteers
- 1,407 people
- Sponsor
- Romark Laboratories L.C.
COVID-19
Study of COVID-19 DNA Vaccine (AG0301-COVID19)
This study will assess the safety and immunogenicity of AG0301-COVID19 in healthy adult volunteers.
- Trial name
- NCT04463472
- Testing
- AG0301-COVID19
- Where
- Japan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AnGes, Inc.
Covid19
The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection
This is an adaptive, Phase I/II study in 2 parts: Part 1 is to evaluate the Maximum Tolerable Dose (MTD) , tolerance, safety and pharmacokinetics of FB2001 in healthy subjects; Part 2 is to evaluate the safety, pharmacokinetics…
- Trial name
- NCT04766931
- Testing
- FB2001
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Frontier Biotechnologies Inc.
Post COVID-19 Syndrome
Intermediate Size Expanded Access Protocol for the Treatment of Post-COVID-19 Syndrome
This is an Intermediate- Size Patient Population Expanded Access Protocol to evaluate the safety and efficacy of HB-adMSCs for the treatment of patients with Post-COVID-19 Syndrome.
- Trial name
- NCT04798066
- Testing
- HB-adMSCs
- Where
- United States
- Sponsor
- Hope Biosciences Research Foundation
COVID-19
Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19
In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome information of a novel coronavirus (SARS-CoV-2) from…
- Trial name
- APLICOV-PC (NCT04382066)
- Testing
- Plitidepsin 1.5 mg/day, Plitidepsin 2.0 mg/day, Plitidepsin 2.5 mg/day
- Where
- 13 sites in Spain
- Volunteers
- 46 people
- Sponsor
- PharmaMar
Covid19
To Evaluate the Safety and Efficacy of TQ Formula in Covid-19 Participants
This is a randomized (1:1), double-blind, placebo-controlled phase 2 study to assess safety and efficacy of Total TQ Formula (3 g daily dose of Nigella Sativa Oil) capsules versus placebo in treating patients who have tested…
- Trial name
- BOSS (NCT04914377)
- Testing
- TQ Formula/Tab
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- Novatek Pharmaceuticals
Coronavirus, Coronavirus Infection
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in patients with moderate…
- Conditions
- Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2, Pneumonia
- Trial name
- CYNKCOVID (NCT04365101)
- Testing
- CYNK-001
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Celularity Incorporated
COVID-19
AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19
In this first-in-humans dose escalation study, AZD7442 (AZD8895 + AZD1061) will be evaluated for safety, tolerability, pharmacokinetics, and generation of anti-drug antibodies (ADAs).
- Trial name
- NCT04507256
- Testing
- AZD7442
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
COVID-19
A Clinical Trial to Evaluate the Efficacy of RUTI® to Reduce the Severity of SARS-CoV-2 Infection (COVID-19)
The aim of this study is to assess the efficacy of the RUTI® vaccine in achieving clinical improvement of COVID-19 symptoms and to evaluate the safety of RUTI® in patients with SARS-CoV-2 infection.
- Trial name
- NCT05115019
- Testing
- RUTI® vaccine
- Sponsor
- PT. Innovative Pharma Solutions
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.